PubMed

Insulin detemir is characterized by a consistent pharmacokinetic profile across age-groups in children, adolescents, and adults with type 1 diabetes.

Danne T, Lüpke K, Walte K, Von Schuetz W, Gall MA.

Diabetes Care. 2003 Nov;26(11):3087-92.PMID: 14578244 [PubMed - indexed for MEDLINE]Related articlesFree article

Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes.

Heise T, Nosek L, Rønn BB, Endahl L, Heinemann L, Kapitza C, Draeger E.

Diabetes. 2004 Jun;53(6):1614-20.PMID: 15161770 [PubMed - indexed for MEDLINE]Related articlesFree article

A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir.

Plank J, Bodenlenz M, Sinner F, Magnes C, Görzer E, Regittnig W, Endahl LA, Draeger E, Zdravkovic M, Pieber TR.

Diabetes Care. 2005 May;28(5):1107-12.PMID: 15855574 [PubMed - indexed for MEDLINE]Related articlesFree article

Comparison of the soluble basal insulin analog insulin detemir with NPH insulin: a randomized open crossover trial in type 1 diabetic subjects on basal-bolus therapy.

Hermansen K, Madsbad S, Perrild H, Kristensen A, Axelsen M.

Diabetes Care. 2001 Feb;24(2):296-301.PMID: 11213882 [PubMed - indexed for MEDLINE]Related articlesFree article

Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen.

Russell-Jones D, Simpson R, Hylleberg B, Draeger E, Bolinder J.

Clin Ther. 2004 May;26(5):724-36.PMID: 15220016 [PubMed - indexed for MEDLINE]Related articles

Proportional dose-response relationship and lower within-patient variability of insulin detemir and NPH insulin in subjects with type 1 diabetes mellitus.

Wutte A, Plank J, Bodenlenz M, Magnes C, Regittnig W, Sinner F, Rønn B, Zdravkovic M, Pieber TR.

Exp Clin Endocrinol Diabetes. 2007 Jul;115(7):461-7.PMID: 17647145 [PubMed - indexed for MEDLINE]Related articles

Insulin detemir is characterized by a more reproducible pharmacokinetic profile than insulin glargine in children and adolescents with type 1 diabetes: results from a randomized, double-blind, controlled trial.

Danne T, Datz N, Endahl L, Haahr H, Nestoris C, Westergaard L, Fjording MS, Kordonouri O.

Pediatr Diabetes. 2008 Dec;9(6):554-60. Epub 2008 Aug 27.PMID: 18761644 [PubMed - indexed for MEDLINE]Related articles

Insulin detemir under steady-state conditions: no accumulation and constant metabolic effect over time with twice daily administration in subjects with Type 1 diabetes.

Bott S, Tusek C, Jacobsen LV, Endahl L, Draeger E, Kapitza C, Heise T.

Diabet Med. 2006 May;23(5):522-8.PMID: 16681561 [PubMed - indexed for MEDLINE]Related articles

Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart.

Vague P, Selam JL, Skeie S, De Leeuw I, Elte JW, Haahr H, Kristensen A, Draeger E.

Diabetes Care. 2003 Mar;26(3):590-6.PMID: 12610006 [PubMed - indexed for MEDLINE]Related articlesFree article

Insulin detemir compared with NPH insulin in children and adolescents with Type 1 diabetes.

Robertson KJ, Schoenle E, Gucev Z, Mordhorst L, Gall MA, Ludvigsson J.

Diabet Med. 2007 Jan;24(1):27-34.PMID: 17227321 [PubMed - indexed for MEDLINE]Related articles

Pharmacokinetics, prandial glucose control, and safety of insulin glulisine in children and adolescents with type 1 diabetes.

Danne T, Becker RH, Heise T, Bittner C, Frick AD, Rave K.

Diabetes Care. 2005 Sep;28(9):2100-5.PMID: 16123473 [PubMed - indexed for MEDLINE]Related articlesFree article

Similarity of insulin detemir pharmacokinetics, safety, and tolerability profiles in healthy caucasian and Japanese american subjects.

Jhee SS, Lyness WH, Rojas PB, Leibowitz MT, Zarotsky V, Jacobsen LV.

J Clin Pharmacol. 2004 Mar;44(3):258-64.PMID: 14973299 [PubMed - indexed for MEDLINE]Related articles

Long-term efficacy and safety of insulin detemir compared to Neutral Protamine Hagedorn insulin in patients with Type 1 diabetes using a treat-to-target basal-bolus regimen with insulin aspart at meals: a 2-year, randomized, controlled trial.

Bartley PC, Bogoev M, Larsen J, Philotheou A.

Diabet Med. 2008 Apr;25(4):442-9.PMID: 18387078 [PubMed - indexed for MEDLINE]Related articlesFree article

Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: a randomized clinical trial.

Home P, Bartley P, Russell-Jones D, Hanaire-Broutin H, Heeg JE, Abrams P, Landin-Olsson M, Hylleberg B, Lang H, Draeger E; Study to Evaluate the Administration of Detemir Insulin Efficacy, Safety and Suitability (STEADINESS) Study Group.

Diabetes Care. 2004 May;27(5):1081-7.PMID: 15111525 [PubMed - indexed for MEDLINE]Related articlesFree article

Effects of multiple daily injection therapy with Humalog mixtures versus separately injected insulin lispro and NPH insulin in adults with type I diabetes mellitus.

Roach P, Bai S, Charbonnel B, Consoli A, Taboga C, Tiengo A, Bolli G; High Mix Study Group.

Clin Ther. 2004 Apr;26(4):502-10.PMID: 15189747 [PubMed - indexed for MEDLINE]Related articles

Improved glycemic control and lower frequency of severe hypoglycemia with insulin detemir; long-term experience in 105 children and adolescents with type 1 diabetes.

Braun D, Konrad D, Lang-Muritano M, Schoenle E.

Pediatr Diabetes. 2008 Aug;9(4 Pt 2):382-7. Epub 2008 Mar 5.PMID: 18331413 [PubMed - indexed for MEDLINE]Related articles

Is insulin detemir able to favor a lower variability in the action of injected insulin in diabetic subjects?

Valensi P, Cosson E.

Diabetes Metab. 2005 Sep;31(4 Pt 2):4S34-4S39. Review.PMID: 16389896 [PubMed - indexed for MEDLINE]Related articles

Spotlight on insulin detemir in type 1 and 2 diabetes mellitus.

Chapman TM, Perry CM.

BioDrugs. 2005;19(1):67-9.PMID: 15691219 [PubMed - indexed for MEDLINE]Related articles

Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes: a double-blind, randomized, crossover study.

Porcellati F, Rossetti P, Busciantella NR, Marzotti S, Lucidi P, Luzio S, Owens DR, Bolli GB, Fanelli CG.

Diabetes Care. 2007 Oct;30(10):2447-52. Epub 2007 Jul 10. Erratum in: Diabetes Care. 2008 Jan;31(1):188. PMID: 17623819 [PubMed - indexed for MEDLINE]Related articlesFree article

Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes.

Klein O, Lynge J, Endahl L, Damholt B, Nosek L, Heise T.

Diabetes Obes Metab. 2007 May;9(3):290-9.PMID: 17391154 [PubMed - indexed for MEDLINE]Related articles